{"name":"ProKidney","slug":"prokidney","ticker":"PROK","exchange":"NASDAQ","domain":"prokidney.com","description":"ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.","hq":"Winston-Salem, NC","founded":0,"employees":"231","ceo":"Pablo Legorreta","sector":"Cell Therapy Biotech","stockPrice":1.73,"stockChange":-0.02,"stockChangePercent":-1.14,"marketCap":"$522M","metrics":{"revenue":893000,"revenueGrowth":196.1,"grossMargin":100,"rdSpend":114123000,"netIncome":-68986000,"cash":108537000,"dividendYield":0,"peRatio":-2.4,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"ProKidney Announces FDA Clearance for REACT Phase 3 Clinical Trial","summary":"ProKidney has received FDA clearance to initiate a phase 3 clinical trial for its Renal Autologous Cell Therapy (REACT) treatment.","drugName":"REACT","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"ProKidney Reports Third Quarter 2023 Financial Results","summary":"ProKidney has reported its third quarter 2023 financial results, with a net loss of $10.2 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE8tYWFXYWNEZW1tQWNLcXVORjBMWl8zV3JSa2poMXFSQ3dXU2gwT3RoZTdLdFczdGpuaXhmX2VIbUhqeUNMRGxVZTlmU2l5SUNDWndKdTZuVUg2eGQ1bWfSAWNBVV95cUxNN0tIZEV2S3dFTkJRbzV4TFFTc3RKX3BOdUV4bnRRTzNrVkp2bkl1U2xidV8xcEVEWW9rMXFaMS1lcmpVVWxEbHBhMEhwTVl5TTJnd2tMbVVWLUZWOXVhX3BfeTQ?oc=5","date":"2026-04-03","type":"pipeline","source":"Bitget","summary":"ProKidney Dips as Institutional Cash Inflows Clash With Bearish Signals - Bitget","headline":"ProKidney Dips as Institutional Cash Inflows Clash With Bearish Signals","sentiment":"neutral"},{"date":"2026-03-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-18","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-12","type":"pipeline","source":"simplywall.st","summary":"3 Promising Penny Stocks With At Least $600M Market Cap - simplywall.st","headline":"3 Promising Penny Stocks With At Least $600M Market Cap","sentiment":"neutral"},{"date":"2026-02-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQU0pTa1Zmckh5WGZIOC1Tc2xsTV9kM3MxNkIyUGNGRG1RRU93YVNNSGR4OU1MQVZiWUowNVp4YWpBRThkbjVYRmdFWUJGVWZpeGQtYk1DLTdqRHdSQWUtWHRuU3Uxalk2UkVPM2ZpdWdNSlRFRFRFQkJJRUJfYU93MVNkbFQ2NjFvazBCaHFrY3Q0M2hTZm1nQmNWMzNicENteHV5NTgxNGlHNGc5VlpjOFRtMjV5cHc?oc=5","date":"2026-01-31","type":"pipeline","source":"Seeking Alpha","summary":"ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK) - Seeking Alpha","headline":"ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK)","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-16","type":"pipeline","source":"simplywall.st","summary":"ProKidney Independent Director Brian Jude Pereira Sells 100% Of Holding - simplywall.st","headline":"ProKidney Independent Director Brian Jude Pereira Sells 100% Of Holding","sentiment":"neutral"},{"date":"2025-11-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-08-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOandtdFJCUUZaZF9rZUxVd2k2SGlqZmZvZmgzVW9pV1RnYjRST3VwaWNKb1lTNVJOeW5SWmlvN1MwRGVPTDNGQmJoTkI5b0dIeE9vdlc4QS10YVpBcmswdWhxNVd6Xy1PcnF6dUhTdm9WS2ZFUDI2ZmlFUVpoVDcwYUtyMlRGTzB1YlE5c0laNmxzUQ?oc=5","date":"2025-07-09","type":"pipeline","source":"Yahoo Finance","summary":"ProKidney, Meta & EssilorLuxottica, Apple COO: Trending Tickers - Yahoo Finance","headline":"ProKidney, Meta & EssilorLuxottica, Apple COO: Trending Tickers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPVF9ockNNMVBMLU1ucDBCSUZoTzB1REFhd1h0WjZ3djRiYURELXBPamJfTEVBaGw0LVU4VWJ2SVB5cldPU3RmYXlwelhOR0pfVW1maGlsV3k5UDJFRmxMZ0lfaHV4ODAxZTI3SUpQZWlwUHphWDU3TzV2T251eG1yNFdmaGQyOXdQaEVZeVl0d0dKREY0SVZOTDgtRWdSclBoYTNSNXd4T1hxdGdoeDdHSFpwVjhMVmlzZDdRV29PZXQzSVBMREU2TjMzcld1SGx3OFFmbXhBdGR5Y3fSAeABQVVfeXFMT05mNllxZE5EWmgxMU05a1MwT3dEd0dhN0pyWnJjOGxEZldZQVlPTnBsajVsYWxkSEo1ZlltWXRQZ1VPQ1VURE1nUFlJeHNtbjQwdkxTYldubFVtbVdiTmJVRHZnUlNKUnFNbzRDanhadGxSZEpMd1hReFVscWhJcUx1ZWxjVHNZVUl3QmlRTTB6MzF6Nm1wcHoxSFRJTkM3V3NuS3lMR19TeDhZMkdPV1Ryc25SanNNZTFVb1JMWkdHZlZlS2VyVm5sSUZOUy1neFdXNTlMRWFYMDhvNEhOYUk?oc=5","date":"2025-07-09","type":"earnings","source":"simplywall.st","summary":"Individual investors who hold 32% of ProKidney Corp. (NASDAQ:PROK) gained 560%, institutions profited as well - simplywall.st","headline":"Individual investors who hold 32% of ProKidney Corp. (NASDAQ:PROK) gained 560%, institutions profited as well","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPcFJmb3pGNXV5MXU0UU1FdUVGZzh5M1Bka0pkTG9GcDRhZmFoaGNQNldMX0NNTE5lamtiZk9mZGZzbmFQd2o4U3pJbjBObWVaYUJvT2FDRmpEQzZrWXlvMVdOSWRYSFdlSlY3WGFiOG1EYUlLQkFsQkxLMmJCRGg5YXRXVW5ZNUIyWFNXSg?oc=5","date":"2025-07-09","type":"trial","source":"The Pharma Letter","summary":"ProKidney soars on new rilparencel data - The Pharma Letter","headline":"ProKidney soars on new rilparencel data","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Akebia Therapeutics","FibroGen","United Therapeutics"],"therapeuticFocus":["Nephrology","Regenerative Medicine"],"financials":{"source":"sec_edgar+yahoo","revenue":893000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":893000},{"period":"2024-12-31","value":76000},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":0}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":114123000,"rdSpendHistory":[{"period":"2025-12-31","value":114123000},{"period":"2024-12-31","value":127668000},{"period":"2023-12-31","value":106707000},{"period":"2022-12-31","value":82070000}],"sgaSpend":51777000,"operatingIncome":-165007000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-165007000},{"period":"2024-12-31","value":-183676000},{"period":"2023-12-31","value":-151522000},{"period":"2022-12-31","value":-153007000}],"netIncome":-68986000,"netIncomeHistory":[{"period":"2025-12-31","value":-68986000},{"period":"2024-12-31","value":-61186000},{"period":"2023-12-31","value":-35468000},{"period":"2022-12-31","value":-108032000}],"eps":-0.52,"epsHistory":[{"period":"2025-12-31","value":-0.52},{"period":"2024-12-31","value":-0.62},{"period":"2023-12-31","value":-0.57},{"period":"2022-12-31","value":-0.23}],"cash":108537000,"cashHistory":[{"period":"2025-12-31","value":108537000},{"period":"2024-12-31","value":99120000},{"period":"2023-12-31","value":60649000},{"period":"2022-12-31","value":490252000}],"totalAssets":335574000,"totalLiabilities":34781000,"totalDebt":4036000,"equity":-1011197000,"operatingCashflow":-120117000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-120117000},{"period":"2024-12-31","value":-126351000},{"period":"2023-12-31","value":-90069000},{"period":"2022-12-31","value":-77089000}],"capex":-15196000,"capexHistory":[{"period":"2025-12-31","value":-15196000},{"period":"2024-12-31","value":-29509000},{"period":"2023-12-31","value":-34197000},{"period":"2022-12-31","value":-1846000}],"freeCashflow":-135313000,"dividendsPaid":null,"buybacks":0,"employees":231,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":11439000,"ebit":-42436000,"ebitda":-40599000,"period":"2025-12-31","revenue":225000,"epsBasic":null,"netIncome":-19231000,"rdExpense":34157000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-45371000},{"sga":11935000,"ebit":-35281000,"ebitda":-33608000,"period":"2025-09-30","revenue":217000,"epsBasic":-0.12,"netIncome":-16469000,"rdExpense":26821000,"epsDiluted":-0.12,"grossProfit":null,"operatingIncome":-38539000},{"sga":14048000,"ebit":-36116000,"ebitda":-34651000,"period":"2025-06-30","revenue":221000,"epsBasic":-0.13,"netIncome":-16552000,"rdExpense":25882000,"epsDiluted":-0.13,"grossProfit":null,"operatingIncome":-39709000},{"sga":14355000,"ebit":-37361000,"ebitda":-35761000,"period":"2025-03-31","revenue":230000,"epsBasic":-0.13,"netIncome":-16734000,"rdExpense":27263000,"epsDiluted":-0.13,"grossProfit":null,"operatingIncome":-41388000},{"sga":11866000,"ebit":-46779000,"ebitda":-45205000,"period":"2024-12-31","revenue":76000,"epsBasic":null,"netIncome":-21278000,"rdExpense":39781000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-51571000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.14,"netIncome":null,"rdExpense":null,"epsDiluted":-0.14,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.73,"previousClose":1.75,"fiftyTwoWeekHigh":7.13,"fiftyTwoWeekLow":0.54,"fiftyTwoWeekRange":"0.54 - 7.13","fiftyDayAverage":1.98,"twoHundredDayAverage":2.34,"beta":1.75,"enterpriseValue":1294409088,"forwardPE":-2.4,"priceToBook":-0.24,"priceToSales":584.99,"enterpriseToRevenue":1449.51,"enterpriseToEbitda":-8.17,"pegRatio":0,"ebitda":-158432000,"ebitdaMargin":0,"freeCashflow":-65267876,"operatingCashflow":-120117000,"totalDebt":4036000,"debtToEquity":1.3,"currentRatio":9.13,"returnOnAssets":-26.6,"returnOnEquity":-43.2,"analystRating":"","recommendationKey":"none","numberOfAnalysts":6,"targetMeanPrice":6.25,"targetHighPrice":12,"targetLowPrice":1,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":68.8,"institutionHeldPercent":34.3,"sharesOutstanding":141987953,"floatShares":93686576,"sharesShort":18263285,"shortRatio":17.84,"shortPercentOfFloat":12.9,"epsTrailing":-0.52,"epsForward":-0.73,"revenuePerShare":0.01,"bookValue":-7.13,"officers":[{"age":56,"name":"Dr. Bruce  Culleton M.D.","title":"CEO & Director"},{"age":48,"name":"Mr. James  Coulston CPA","title":"Chief Financial Officer"},{"age":60,"name":"Mr. Todd C. Girolamo Esq., J.D., M.B.A.","title":"Chief Legal Officer & Secretary"},{"age":62,"name":"Dr. Ulrich  Ernst Ph.D.","title":"EVP of Science and Technology"},{"age":null,"name":"Mr. Richard  Williams","title":"Chief Information Officer"},{"age":null,"name":"Ms. Carla  Poulson","title":"Chief People Officer"},{"age":null,"name":"Dr. Joseph M. Stavas M.D., M.P.H.","title":"SVP of Clinical Affairs"},{"age":57,"name":"Dr. Darin J. Weber Ph.D.","title":"Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access"}],"industry":"Biotechnology","irWebsite":"","website":"https://prokidney.com","phone":"336 999 7019"}}